$170.10
al cierre: Oct 7 EDT
$170.10
0.000.00%
Pre-comercialización: 4:00 PM EDT
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Charles River Laboratories International Inc ha un obiettivo di prezzo di consenso pari a $197.06, stabilito in base alle ultime valutazioni degli analisti di 21. Le ultime 3 valutazioni degli analisti sono state rilasciate da Evercore ISI Group, Barclays y Jefferies il octubre 3, 2025, octubre 2, 2025 y septiembre 9, 2025. Con un obiettivo di prezzo medio di $196.67 tra le Evercore ISI Group, Barclays y Jefferies, c'è un implicito 15.62% upside per Charles River Laboratories International Inc da queste valutazioni degli analisti.
Firmas de analistas que realizan recomendaciones1
Evercore ISI Group
Barclays
Jefferies
JP Morgan
Citigroup
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Charles River
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/06/2025 | — | William Blair | — | Upgrade | Market Perform → Outperform | |||
10/03/2025 | 17.58% | Evercore ISI Group | $190 → $200 | Maintains | Outperform | |||
10/02/2025 | 14.64% | Barclays | $165 → $195 | Upgrade | Equal-Weight → Overweight | |||
09/09/2025 | 14.64% | Jefferies | $142 → $195 | Upgrade | Hold → Buy | |||
08/08/2025 | 11.7% | Evercore ISI Group | $180 → $190 | Maintains | Outperform | |||
08/07/2025 | -5.94% | JP Morgan | $145 → $160 | Maintains | Neutral | |||
08/07/2025 | -3% | Barclays | $155 → $165 | Maintains | Equal-Weight | |||
07/09/2025 | 5.82% | Evercore ISI Group | $170 → $180 | Maintains | Outperform | |||
07/09/2025 | 17.58% | Citigroup | $150 → $200 | Upgrade | Neutral → Buy | |||
05/23/2025 | 7% | Redburn Atlantic | $188 → $182 | Upgrade | Neutral → Buy | |||
05/08/2025 | -8.88% | Barclays | $145 → $155 | Maintains | Equal-Weight | |||
05/08/2025 | -17.7% | Baird | $118 → $140 | Maintains | Neutral | |||
04/10/2025 | -14.76% | Barclays | $160 → $145 | Maintains | Equal-Weight | |||
04/09/2025 | -8.88% | Mizuho | $175 → $155 | Maintains | Neutral | |||
03/21/2025 | -0.06% | Goldman Sachs | $190 → $170 | Downgrade | Buy → Neutral | |||
03/04/2025 | 2.88% | Citigroup | $155 → $175 | Upgrade | Sell → Neutral | |||
03/03/2025 | 10.52% | Redburn Atlantic | $171 → $188 | Upgrade | Sell → Neutral | |||
02/20/2025 | -3% | JP Morgan | $175 → $165 | Maintains | Neutral | |||
02/20/2025 | 1.7% | Baird | $177 → $173 | Maintains | Neutral | |||
02/20/2025 | -5.94% | Barclays | $166 → $160 | Maintains | Equal-Weight | |||
02/18/2025 | -2.41% | Barclays | $205 → $166 | Maintains | Equal-Weight | |||
02/05/2025 | 8.17% | Morgan Stanley | $220 → $184 | Maintains | Equal-Weight | |||
02/03/2025 | 2.88% | JP Morgan | $215 → $175 | Maintains | Neutral | |||
01/23/2025 | 11.7% | Goldman Sachs | $220 → $190 | Maintains | Buy | |||
01/22/2025 | — | William Blair | — | Downgrade | Outperform → Market Perform | |||
01/17/2025 | 8.76% | UBS | $250 → $185 | Downgrade | Buy → Neutral | |||
01/14/2025 | — | William Blair | — | Reiterates | Outperform → Outperform | |||
12/16/2024 | 29.34% | Morgan Stanley | $225 → $220 | Maintains | Equal-Weight | |||
12/13/2024 | 23.46% | B of A Securities | $220 → $210 | Maintains | Neutral | |||
11/11/2024 | 33.45% | TD Cowen | $203 → $227 | Maintains | Hold | |||
11/07/2024 | 46.97% | UBS | $240 → $250 | Maintains | Buy | |||
11/07/2024 | 32.28% | Evercore ISI Group | $190 → $225 | Maintains | In-Line | |||
10/23/2024 | -1.82% | CLSA | — | → $167 | Initiates | → Underperform | ||
10/16/2024 | 20.52% | Barclays | $210 → $205 | Maintains | Equal-Weight | |||
10/14/2024 | -11.23% | Redburn Atlantic | → $151 | Initiates | → Sell | |||
10/07/2024 | 11.7% | Evercore ISI Group | $225 → $190 | Downgrade | Outperform → In-Line | |||
10/02/2024 | 26.4% | B of A Securities | $250 → $215 | Downgrade | Buy → Neutral | |||
10/01/2024 | 2.88% | Citigroup | $215 → $175 | Downgrade | Neutral → Sell | |||
09/20/2024 | 11.7% | Baird | $191 → $190 | Maintains | Neutral | |||
08/12/2024 | 19.34% | TD Cowen | $228 → $203 | Maintains | Hold | |||
08/08/2024 | 26.4% | Morgan Stanley | $235 → $215 | Maintains | Equal-Weight | |||
08/08/2024 | 23.46% | Barclays | $230 → $210 | Maintains | Equal-Weight | |||
08/08/2024 | 41.09% | UBS | $290 → $240 | Maintains | Buy | |||
08/08/2024 | 32.28% | Evercore ISI Group | $265 → $225 | Maintains | Outperform | |||
08/08/2024 | 46.97% | Goldman Sachs | $290 → $250 | Maintains | Buy | |||
08/08/2024 | 20.52% | JP Morgan | $270 → $205 | Downgrade | Overweight → Neutral | |||
08/08/2024 | 12.29% | Baird | $239 → $191 | Downgrade | Outperform → Neutral | |||
07/10/2024 | 40.51% | Baird | $271 → $239 | Maintains | Outperform | |||
06/28/2024 | 35.21% | Barclays | → $230 | Initiates | → Equal-Weight | |||
06/28/2024 | — | Argus Research | — | Downgrade | Buy → Hold | |||
06/07/2024 | 38.15% | Mizuho | → $235 | Initiates | → Neutral | |||
06/06/2024 | 70.49% | Goldman Sachs | → $290 | Initiates | → Buy | |||
05/13/2024 | 34.04% | TD Cowen | $260 → $228 | Maintains | Hold | |||
05/10/2024 | 58.73% | Baird | $282 → $270 | Maintains | Outperform | |||
03/18/2024 | 70.49% | Argus Research | $240 → $290 | Maintains | Buy | |||
02/15/2024 | 64.61% | JP Morgan | $270 → $280 | Maintains | Overweight | |||
02/15/2024 | 55.79% | Evercore ISI Group | $260 → $265 | Maintains | Outperform | |||
02/15/2024 | 70.49% | UBS | $270 → $290 | Maintains | Buy | |||
02/15/2024 | 46.97% | Citigroup | $215 → $250 | Maintains | Neutral | |||
02/15/2024 | 57.55% | Baird | $252 → $268 | Maintains | Outperform | |||
02/15/2024 | — | Guggenheim | — | Downgrade | Buy → Neutral | |||
12/20/2023 | 58.73% | JP Morgan | $210 → $270 | Maintains | Overweight | |||
12/11/2023 | 26.4% | Citigroup | $190 → $215 | Maintains | Neutral | |||
11/10/2023 | 20.52% | Morgan Stanley | $220 → $205 | Maintains | Equal-Weight | |||
11/09/2023 | 26.4% | UBS | $250 → $215 | Maintains | Buy | |||
10/24/2023 | 29.34% | Morgan Stanley | $235 → $220 | Maintains | Equal-Weight | |||
09/25/2023 | 22.87% | TD Cowen | $212 → $209 | Maintains | Market Perform | |||
09/22/2023 | 50.5% | Baird | $267 → $256 | Maintains | Outperform | |||
09/22/2023 | 32.28% | Guggenheim | $255 → $225 | Maintains | Buy | |||
09/22/2023 | 61.67% | Wells Fargo | $280 → $275 | Maintains | Overweight | |||
09/13/2023 | 24.63% | TD Cowen | → $212 | Initiates | → Market Perform | |||
08/10/2023 | 46.97% | JP Morgan | $225 → $250 | Maintains | Overweight | |||
08/10/2023 | 44.03% | B of A Securities | $235 → $245 | Maintains | Buy | |||
07/11/2023 | 32.28% | Citigroup | $260 → $225 | Downgrade | Buy → Neutral | |||
07/10/2023 | 32.28% | Citigroup | $260 → $225 | Downgrade | Buy → Neutral | |||
05/15/2023 | 32.28% | Morgan Stanley | $230 → $225 | Maintains | Equal-Weight | |||
05/12/2023 | 49.91% | Credit Suisse | $260 → $255 | Maintains | Outperform | |||
05/12/2023 | 64.61% | Wells Fargo | $290 → $280 | Maintains | Overweight | |||
03/28/2023 | 19.34% | Jefferies | $233 → $203 | Maintains | Hold | |||
02/23/2023 | 52.85% | Credit Suisse | $280 → $260 | Maintains | Outperform | |||
02/23/2023 | 35.21% | Morgan Stanley | $241 → $230 | Maintains | Equal-Weight | |||
02/23/2023 | 52.85% | Citigroup | $280 → $260 | Maintains | Buy | |||
02/23/2023 | 49.91% | Guggenheim | → $255 | Upgrade | Neutral → Buy | |||
01/12/2023 | — | Jefferies | — | Downgrade | Buy → Hold | |||
01/11/2023 | 67.55% | Baird | $275 → $285 | Maintains | Outperform | |||
11/03/2022 | 61.67% | JP Morgan | $280 → $275 | Maintains | Overweight | |||
11/03/2022 | 64.61% | Credit Suisse | $285 → $280 | Maintains | Outperform | |||
11/03/2022 | 41.68% | Morgan Stanley | $250 → $241 | Maintains | Equal-Weight |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Charles River (CRL)?
El último precio objetivo de Charles River (NYSE:CRL) fue comunicado por William Blair el octubre 6, 2025. La firma de analistas fijó un precio objetivo para $0.00 que espera CRL a fall dentro de 12 meses (un posible -100.00% downside). 35 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Charles River (CRL)?
La última calificación de analistas para Charles River (NYSE:CRL) fue proporcionada por William Blair, y Charles River mejorado su outperform calificación.
¿Cuándo se produjo la última revisión al alza de Charles River (CRL)?
La última revisión al alza de Charles River Laboratories International Inc se produjo en octubre 6, 2025, cuando William Blair elevó su precio objetivo a N/A. William Blair anteriormente tenía a market perform para Charles River Laboratories International Inc.
¿Cuándo fue la última revisión a la baja de Charles River (CRL)?
La última revisión a la baja de Charles River Laboratories International Inc se produjo en marzo 21, 2025, cuando Goldman Sachs cambió su precio objetivo de $190 a $170 para Charles River Laboratories International Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Charles River (CRL)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Charles River, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Charles River se registró el octubre 6, 2025, por lo que la próxima calificación estará disponible en torno al octubre 6, 2026.
¿Es correcta la calificación de los analistas sobre Charles River (CRL)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Charles River (CRL) fue un mejorado con un precio objetivo de $0.00 a $0.00. El precio actual al que cotiza Charles River (CRL) es de $170.10, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.